Focused On-demand Library for ATP-dependent zinc metalloprotease YME1L1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.







Alternative names:

ATP-dependent metalloprotease FtsH1; Meg-4; Presenilin-associated metalloprotease; YME1-like protein 1

Alternative UPACC:

Q96TA2; B4DNM1; D3DRV8; D3DRV9; Q5T8D9; Q9H1Q0; Q9UMR9


ATP-dependent zinc metalloprotease YME1L1, also known as ATP-dependent metalloprotease FtsH1, Meg-4, Presenilin-associated metalloprotease, and YME1-like protein 1, plays a pivotal role in mitochondrial function. It catalyzes the degradation of proteins within the mitochondrial intermembrane space, crucial for maintaining mitochondrial morphology, protein metabolism, and cell proliferation. YME1L1's activity is essential for the normal structure of mitochondria, influencing cristae morphology and complex I respiration.

Therapeutic significance:

YME1L1's involvement in Optic atrophy 11, a disease marked by progressive visual loss and neurological symptoms, underscores its therapeutic potential. Understanding YME1L1's role could pave the way for novel treatments targeting mitochondrial dysfunctions in neurodegenerative diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.